Gabriel Broocks
Jens Minnerup
Shervin Kamalian
Andre Kemmling
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
- 1Department of Neuroradiology, HELIOS Medical Center, Campus of MSH Medical School Hamburg, Schwerin, Germany
- 2Department of Neurology, University Hospital Lübeck, Lübeck, Germany
- 3Department of Neuroradiology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA, United States
- 4Department of Neuroradiology, University Marburg, Marburg, Germany
Editorial on the Research Topic
Novel approaches in diagnosis and management of ischemic edema in large vessel occlusion stroke, volume II
Introduction
Recently, randomized controlled trials (RCTs) have confirmed that endovascular thrombectomy (EVT) significantly improves functional outcome and survival in patients with anterior stroke presenting with large early infarct lesions on standard imaging, compared to best medical treatment (BMT) alone (1–6). Additionally, it has been observed that the effect of recanalization on functional outcome is mediated by edema reduction as an important mechanism explaining the treatment effect particularly in large strokes. Still, there is only very limited proof of effective adjuvant treatment options to further reduce the impact of edema formation. The aim of this Research Topic was (1) to investigate further potential adjuvant treatment strategies for ischemic stroke and (2) to discuss novel prediction models for the assessment of secondary injury volumes directly affecting functional outcome.
Novel prediction models and imaging techniques
The early identification of patients at risk of developing potentially malignant brain edema is of significant clinical relevance. Liu et al. systematically evaluated prediction models for post-thrombectomy brain edema in acute ischemic stroke patients. The authors observed a high risk of bias after analyzing 10 models and emphasized the need for large-scale, multicenter studies to develop robust models for real-world clinical applications (Liu et al.). Similarly, Ma et al. investigated intracranial hemorrhage as further secondary injury after stroke using a nomogram prediction model including 197 stroke patients receiving intravenous thrombolysis with alteplase. The highest diagnostic accuracy to predict secondary hemorrhage was observed for a nomogram including NIHSS, NT-pro BNP, neutrophil to lymphocyte ratio, and systolic blood pressure (Ma et al.).
A further nomogram analysis for outcome prediction in stroke patients was used by Xie et al. specifically to predict the risk for malignant cerebral edema. After inclusion of 312 patients, the developed nomogram based on LASSO-logistic regression was an accurate predictor of malignant edema showing an AUC of 0.89 (Xie et al.). Pham and Ng comprehensively discussed the currently available advanced imaging techniques for cerebral edema in ischemic stroke. Several techniques exist, however, many challenges remain that must be met before clinical application is possible.
Novel strategies for the management of vasogenic edema after stroke
Several drugs have been tested as options for adjuvant treatment and neuroprotection in ischemic stroke over decades. Despite many promising animal studies, there is yet no effective and established treatment available to further improve functional outcome (7). Yet, a majority of these trials were including patients not undergoing successful endovascular treatment (8). The combination of reperfusion with adjuvant treatment might bring forth new strategies to improve functional outcome (8). Pan et al. presented a phase 1 clinical trial using Albumin as adjuvant treatment option, which previously showed neuroprotective effects in an animal population. The authors aimed to investigate the safety and efficacy of arterial infusion of an albumin solution after recanalization. The authors expected to provide data for subsequent studies on the arterial infusion of albumin solutions (Pan et al.). A further strategy for neuroprotection might consist of epidermal growth factor and growth hormone-releasing hexapeptide. Hernández-Bernal et al. on behalf of the (COmbined therapeUtic appRoAch durinG acute strokE) COURAGE group presented a phase I/II randomized clinical trial and concluded that the administration of these agents was safe and a phase III study may bring forth promising clinical benefits. Finally, Yan et al. discussed protective effects of butyrate on ischemic injury in animal models aiming to provide a scientific basis for the clinical application of butyrate in stroke patients. It was concluded that butyrate may exhibit a protective effect in animals relating to reduced inflammation and inhibition of apoptosis based on the analysis of nine studies (Yan et al.).
Discussion and future challenges
Recently, the publication of the large core trials further expanded the indication for EVT to patients that were previously often excluded from treatment. Demonstrating a significant clinical benefit of vessel recanalization in patients despite already showing signs of significant lesion progression challenges adhered dogmas of treatment decision-making with implications for the treatment of ischemic stroke in general (9). As last frontiers, the effect of EVT for patients presenting with distal vessel occlusions and low NIHSS is currently being investigated in several randomized trials (10).
Nevertheless, the treatment effect of reperfusion especially in large stroke is not well-understood and requires further investigation. The degree of early edema formation in ischemic stroke, which can be determined for instance using CT densitometry, has not yet been considered as image criterion for treatment selection, which could potentially be an important modifier of the therapy effect of recanalization (11). Furthermore, secondary treatment effects like edema reduction may be the link between better functional outcome despite a large infarct. In this context, adjuvant treatment options targeting edema formation may be of interest (12). In the CHARM trial (NCT02864953), the safety and efficacy of intravenous glibenclamide to treat cerebral edema was investigated after previous studies observed that glibenclamide administration was associated with reduced edema formation and better functional outcome (13, 14). However, in patients undergoing EVT, the administration of this drug in this study was only applied after the EVT procedure and after performing a further DWI-MRI examination, which is a significant limitation, also considering that this trial was originally not designed to evaluate patients undergoing EVT. In the future, the timely administration of glibenclamide in combination with other neuroprotectants and in the context of endovascular recanalization may lead to better outcomes in ischemic stroke.
Author contributions
GB: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. JM: Writing – original draft, Writing – review & editing. SK: Writing – original draft, Writing – review & editing. AK: Writing – original draft, Writing – review & editing.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Bendszus M, Fiehler J, Subtil F, Bonekamp S, Aamodt AH, Fuentes B, et al. Endovascular thrombectomy for acute ischaemic stroke with established large infarct: multicentre, open-label, randomised trial. Lancet. (2023) 402:1753–63. doi: 10.1016/S0140-6736(23)02032-9
2. Costalat V, Jovin TG, Albucher JF, Cognard C, Henon H, Nouri N, et al. Trial of thrombectomy for stroke with a large infarct of unrestricted size. N Engl J Med. (2024) 390:1677–89. doi: 10.1056/NEJMoa2314063
3. Huo X, Ma G, Tong X, Zhang X, Pan Y, Nguyen TN, et al. Trial of endovascular therapy for acute ischemic stroke with large infarct. N Engl J Med. (2023) 388:1272–83. doi: 10.1056/NEJMoa2213379
4. Writing Committee for the TESLA Investigators Yoo AJ Zaidat OO Sheth SA Rai AT Ortega-Gutierrez S . Thrombectomy for stroke with large infarct on noncontrast CT: the TESLA randomized clinical trial. JAMA. (2024) 332:1355–66. doi: 10.1001/jama.2024.13933
5. Sarraj A, Hassan AE, Abraham MG, Ortega-Gutierrez S, Kasner SE, Hussain MS, et al. Trial of endovascular thrombectomy for large ischemic strokes. N Engl J Med. (2023). 388:1259–71. doi: 10.1056/NEJMoa2214403
6. Yoshimura S, Sakai N, Yamagami H, Uchida K, Beppu M, Toyoda K, et al. Endovascular therapy for acute stroke with a large ischemic region. N Engl J Med. (2022) 386:1303–13. doi: 10.1056/NEJMoa2118191
7. Schmidt-Pogoda A, Bonberg N, Koecke MHM, Strecker JK, Wellmann J, Bruckmann NM, et al. Why most acute stroke studies are positive in animals but not in patients: a systematic comparison of preclinical, early phase, and phase 3 clinical trials of neuroprotective agents. Ann Neurol. (2020) 87:40–51. doi: 10.1002/ana.25643
8. Shi L, Rocha M, Leak RK, Zhao J, Bhatia TN, Mu H, et al. A new era for stroke therapy: Integrating neurovascular protection with optimal reperfusion. J Cereb Blood Flow Metab. (2018) 38:2073–91. doi: 10.1177/0271678X18798162
9. Deb-Chatterji M, Pinnschmidt H, Flottmann F, Leischner H, Broocks G, Alegiani A, et al. Predictors of independent outcome of thrombectomy in stroke patients with large baseline infarcts in clinical practice: a multicenter analysis. J Neurointerv Surg. (2020) 12:1064–8. doi: 10.1136/neurintsurg-2019-015641
10. Saver JL, Chapot R, Agid R, Hassan A, Jadhav AP, Liebeskind DS, et al. Thrombectomy for distal, medium vessel occlusions: a consensus statement on present knowledge and promising directions. Stroke. (2020) 51:2872–84. doi: 10.1161/STROKEAHA.120.028956
11. Broocks G, Meyer L, Elsayed S, McDonough R, Bechstein M, Faizy TD, et al. Association between net water uptake and functional outcome in patients with low ASPECTS brain lesions: results from the I-LAST study. Neurology. (2023) 100:e954–63. doi: 10.1212/WNL.0000000000201601
12. Broocks G, Kemmling A, Kniep H, Meyer L, Faizy TD, Hanning U, et al. Edema reduction versus penumbra salvage: investigating treatment effects of mechanical thrombectomy in ischemic stroke. Ann Neurol. (2024) 95:137–45. doi: 10.1002/ana.26802
13. Vorasayan P, Bevers MB, Beslow LA, Sze G, Molyneaux BJ, Hinson HE, et al. Intravenous Glibenclamide reduces lesional water uptake in large hemispheric infarction. Stroke. (2019) 50:3021–7. doi: 10.1161/STROKEAHA.119.026036
14. Sheth KN, Elm JJ, Molyneaux BJ, Hinson H, Beslow LA, Sze GK, et al. Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. (2016) 15:1160–9. doi: 10.1016/S1474-4422(16)30196-X
Keywords: stroke, thrombectomy, imaging—computed tomography, neuroprotection, ischemia—reperfusion
Citation: Broocks G, Minnerup J, Kamalian S and Kemmling A (2025) Editorial: Novel approaches in diagnosis and management of ischemic edema in large vessel occlusion stroke, volume II. Front. Neurol. 16:1568007. doi: 10.3389/fneur.2025.1568007
Received: 28 January 2025; Accepted: 10 February 2025;
Published: 19 February 2025.
Edited and reviewed by: Jean-Claude Baron, University of Cambridge, United Kingdom
Copyright © 2025 Broocks, Minnerup, Kamalian and Kemmling. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Gabriel Broocks, Z2FicmllbC5icm9vY2tzQG1lZGljYWxzY2hvb2wtaGFtYnVyZy5kZQ==